A. Carr, K. Samaras, A. Thorisdottir, G. R. Kaufmann, D. J. Chisholm and D. A. Cooper, “Diagnosis, Prediction, and Natural Course of HIV-1 Protease-Inhibitor-Associated Lipodystrophy, Hyperlipidaemia, and Diabetes Mellitus: A Cohort Study,” The Lancet, Vol. 353, No. 9170, 1999, pp. 2093-2099. doi:10.1016/S0140-6736(98)08468-2

has been cited by the following article:

• TITLE: Lipodystrophy of HIV (LDHIV) in the Head and Neck: Imaging and Clinical Features

  AUTHORS: Saman Hazany, Rafael Rojas, Gul Moonis

  KEYWORDS: Lipodystrophy of HIV; LDHIV; Protease Inhibitor

  JOURNAL NAME: International Journal of Otolaryngology and Head & Neck Surgery, Vol.1 No.2, August 20, 2012

  ABSTRACT: A subset of HIV-1 infected patients undergoing antiretroviral treatment with HIV-1 protease inhibitors (PI’s) develops a syndrome called Lipodystrophy of HIV (LDHIV). LDHIV is characterized by loss of peripheral subcutaneous adipose tissue (face, limbs, buttocks), visceral fat accumulation, and in some cases, lipomatosis in the neck and dorsocervical area .We describe the clinical and imaging features of LDHIV in the head and neck in a series of 5 cases. There is a consistent pattern of fat accumulation in the dorsocervical region with paucity of fat in the face. This classic appearance should be recognized as potentially related to drug toxicity in the HIV infected population.